Phase 3 N=122 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Prostate Adenocarcinoma
Primary: Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI — 92; 127 number of tumor lesions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…
Phase 2 N=25 FACBC for Recurrent Prostate Cancer
Recurrent Prostate Cancer
Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants
Phase 2 N=6 Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With a Toxicity — 6; 7; 24 Percentage of participants
Phase 2 N=23 Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: PSA Response — 0 participants
Phase 3 N=346 Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
Prostate Cancer
Primary: True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up
Phase 3 N=385 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Prostate Cancer
Primary: Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation — 0.90 percentage of times value is true
Phase 2 N=21 Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
Prostate Adenocarcinoma · Recurrent Prostate Carcinoma · Stage I Prostate Adenocarcinoma AJCC v7
Primary: Number of Patients Who Achieve a Greater Than or Equal to 50% Decline in Serum Prostate Specific Antigen (PSA) — 1 Participants
Phase 3 N=109 Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Metastatic Prostate Cancer
Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants
Phase 3 N=109 Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
Cancer of the Prostate
Primary: Impact on Patient Treatment /Management — 66; 38; 53; 5 Participants
Phase 2 N=10 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Recurrent Prostate Carcinoma
Primary: Average SUVmax of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution — 12.4 SUVmax
Phase 2 N=93 FACBC PET/CT for Recurrent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With True Positive Scans Within the Prostate Bed — 55; 41 participants
Phase 2 N=53 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
Biochemical Recurrence of Malignant Neoplasm of Prostate
Primary: Safety and Tolerability — 8; 8; 0; 0 Participants
Phase 1 N=17 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Prostate Cancer · Prostatic Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)
Phase 2 N=60 Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Prostate Cancer
Primary: Safety, Feasibility and Tolerance of Revlimid as Assessed by Number of Participants Experiencing Grade 3 and 4 Adverse Events. — 3; 10 Participants
Phase 2 N=29 Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
Cancer of Prostate
Primary: Biochemical Response Rate Based on PSA — 3; 5 Participants
Phase 2 N=52 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
Biochemical Recurrence of Malignant Neoplasm of Prostate
Primary: Safety and Tolerability — 10; 8; 2; 0 Participants
Phase 2 N=1,435 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Prostate Cancer · Prostate Adenocarcinoma · Prostate Cancer Metastatic
Primary: Positive Predictive Value (PPV) of 68Ga PSMA PET/CT for Detecting Prostate Cancer on a Per-patient Basis Confirmed by Histopathology. — 87.3 percentage of times value is…
N/A N=19 Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)
Prostate Cancer
Primary: Proportion of Subjects With a Demethylation Response at Each Dose Level — .22; .30 proportion of participants
Phase 2 N=90 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale
Phase 2 N=35 RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Biochemical Response Rate — 0 participants
Phase 3 N=61 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Prostate Adenocarcinoma · PSA Failure · Recurrent Prostate Carcinoma
Primary: Confirmation of Prostate Cancer Recurrence by 68Ga-PSMA-11 PET/CT — 46; 15 Participants
Phase 2 N=41 Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT) — 98 percentage of participants with data
Phase 3 N=190 Study of Diagnostic Performance of [18F]CTT1057 in BCR
Prostatic Neoplasms · Prostate Cancer · Recurrence
Primary: Region-level Correct Localization Rate (CLR) of Vidoflufolastat (18F) — 75.0; 68.9; 65.2 Percentage of regions
Phase 2 N=102 Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Prostate Cancer
Primary: Relapse-free Survival — 13; 10 months
Phase 1 N=21 Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer Recurrent · Prostate Cancer · Prostate Adenocarcinoma
Primary: Number of Participants With Dose-limiting Toxicities (Treatment-related Adverse Events) as Assessed by the CTCAE v5.0 — 0; 0; 0 Participants
Phase 3 N=30 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
Prostate Cancer · Prostatic Neoplasm · Prostatic Neoplasms, Castration-Resistant
Primary: Sensitivity of Ga 68-labeled PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) for the Detection on a Per Patient Basis — 1.0 proportion of participants
Phase 3 N=840 Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
Prostate Cancer
Primary: Overall Survival (12-year Rates Reported) — 71.3; 76.3 percentage of participants — p=0.020
Phase 3 N=165 FACBC Outcomes for Post Prostatectomy
Prostate Cancer
Primary: Failure-free Survival — 75.5; 63.0 Percentage of participants